1326 related articles for article (PubMed ID: 28493171)
1. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
2. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
Sundararajan S; Vogelzang NJ
Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808
[TBL] [Abstract][Full Text] [Related]
5. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors: a new frontier in bladder cancer.
Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
[TBL] [Abstract][Full Text] [Related]
8. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
12. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
13. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitors in bladder and renal cancers: results and perspectives.
Aoun F; Kourie HR; Sideris S; Roumeguère T; van Velthoven R; Gil T
Immunotherapy; 2015; 7(12):1259-71. PubMed ID: 26595284
[TBL] [Abstract][Full Text] [Related]
15. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
16. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 inhibitors.
Sunshine J; Taube JM
Curr Opin Pharmacol; 2015 Aug; 23():32-8. PubMed ID: 26047524
[TBL] [Abstract][Full Text] [Related]
18. The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.
Bardoli AD; Afshar M; Viney R; Foster M; Porfiri E; Zarkar A; Stevenson R; James ND; Bryan RT; Patel P
Future Oncol; 2016 Mar; 12(5):595-600. PubMed ID: 26880382
[No Abstract] [Full Text] [Related]
19. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in lung cancer: past, present and future.
Seetharamu N; Budman DR; Sullivan KM
Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]